{
  "main_header": {
    "sid": 621096,
    "name": "Colinz Labs",
    "stock_name": "Colinz Labs",
    "full_name": "Colinz Laboratories Ltd",
    "name_url": "stocks-analysis/colinz-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "52.95",
    "chg": -1.31,
    "chgp": "-2.41%",
    "dir": -1,
    "prev_price": "54.26",
    "mcapval": "24.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531210,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE923C01011",
    "curr_date": "Dec 17",
    "curr_time": "",
    "bse_nse_vol": "2.63 k",
    "exc_status": "Active",
    "traded_date": "Dec 17, 2025",
    "traded_date_str": "2025 12 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/colinz-labs-621096-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Colinz Labs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-colinz-labs-fallingrising-3759014",
        "imagepath": "",
        "date": "2025-12-16 00:31:17",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Colinz Laboratories has demonstrated a remarkable rebound over the past week and month, with returns of +11.36% and +14.65% respectively, significantly outpacing the Sensex benchmark, which posted marginal gains of +0.13% and +0.77% over the same periods. This outperformance is particularly striking given the stock's year-to-date decline of nearly 30%, contrasting with the Sensex's positive 9.05% gain. The divergence suggests that investors are beginning to reassess the stock's prospects, possibly anticipating a turnaround or capitalising on recent technical signals.</p>\n<p>Over the longer term, Colinz Labs has delivered a robust five-year return of +241.46%, well above the Sensex's +84.19%, underscoring its potential for substantia..."
      },
      {
        "title": "Colinz Labs Sees Revision in Market Evaluation Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/colinz-labs-downgraded-to-strong-sell-amid-weak-fundamentals-and-valuation-concerns-3753349",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ColinzLabs_mojoScore_3753349.png",
        "date": "2025-12-09 10:10:07",
        "description": "Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry."
      },
      {
        "title": "Why is Colinz Labs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-colinz-labs-fallingrising-3702316",
        "imagepath": "",
        "date": "2025-11-14 21:44:17",
        "description": "As of 14-Nov, Colinz Laboratories Ltd is experiencing a price increase, currently at 42.74, which reflects a rise of 0.94 or 2.25%. The stock has shown strong performance recently, gaining for four consecutive days and achieving a total return of 7.49% during this period. Additionally, it has outperformed its sector by 1.88%. In terms of returns compared to the benchmark, over the past week, the stock has increased by 2.91%, while the Sensex has risen by 1.62%. The stock's delivery volume has also seen a significant increase of 48.13% compared to the five-day average, indicating rising investor participation. However, it is important to note that there is no information available regarding any positive or negative factors that could further explain the stock's recent movement.\n\nBroader Market Context: In the short term, Colinz Laboratories Ltd has outperformed the Sensex, which suggests that investor sentim..."
      },
      {
        "title": "Colinz Laboratories Hits New 52-Week Low at Rs. 36.11",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-hits-new-52-week-low-at-rs-3611-3696966",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ColinzLaborator_priceRelatedfactors_3696966.png",
        "date": "2025-11-13 09:58:38",
        "description": "Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance."
      },
      {
        "title": "Colinz Laboratories Hits New 52-Week Low at Rs. 37.4",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-hits-new-52-week-low-at-rs-374-3689984",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ColinzLaborator_priceRelatedfactors_3689984.png",
        "date": "2025-11-11 14:13:49",
        "description": "Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market."
      },
      {
        "title": "Why is Colinz Labs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-colinz-labs-fallingrising-3676571",
        "imagepath": "",
        "date": "2025-11-06 21:25:46",
        "description": "As of 06-Nov, Colinz Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 39.81, which represents a decrease of 4.42 or 9.99%. The stock has underperformed its sector by 9.22% today and has opened with a loss of 4.07%. It has touched an intraday low of Rs 39.81, indicating significant selling pressure. The stock has also fallen after two consecutive days of gains, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 77.12% against the 5-day average. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Colinz Laboratories Ltd's performance over the past week shows a decline of 9.48%, while the benchmark Sensex has only decrea..."
      },
      {
        "title": "Colinz Laboratories Ltd Faces 9.99% Decline Amid Significant Selling Pressure and Ongoing Losses",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/colinz-laboratories-ltd-faces-999-decline-amid-significant-selling-pressure-and-ongoing-losses-3675987",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ColinzLaborator_only_sellers_3675987.png",
        "date": "2025-11-06 14:35:28",
        "description": "Colinz Laboratories Ltd is experiencing substantial selling pressure, with its stock declining significantly over various time frames. The company has faced consecutive losses, underperforming against the Sensex and its sector. Factors contributing to this trend include trading below key moving averages and ongoing challenges in its market position."
      },
      {
        "title": "Are Colinz Labs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-colinz-labs-latest-results-good-or-bad-3671639",
        "imagepath": "",
        "date": "2025-11-04 19:45:34",
        "description": "Colinz Laboratories' latest financial results for Q2 FY26 reveal a complex operational landscape characterized by significant challenges. The company reported net sales of ₹1.39 crores, reflecting a decline of 11.46% from the previous quarter and a more pronounced year-on-year decrease of 25.27%. This trend indicates ongoing difficulties in maintaining revenue momentum, as the company has now experienced negative growth in sales for several consecutive quarters.\n\nDespite the revenue decline, Colinz Laboratories reported a net profit of ₹0.14 crores, which represents a sequential improvement of 16.67% compared to the previous quarter. However, this figure is down 12.50% year-on-year, suggesting that while there may be some short-term resilience in net profit, the overall financial health remains under pressure due to the declining top-line performance.\n\nOperating margins also faced significant compression, w..."
      },
      {
        "title": "Is Colinz Labs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-colinz-labs-overvalued-or-undervalued-3668665",
        "imagepath": "",
        "date": "2025-11-04 08:06:53",
        "description": "As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.\n\nDespite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers...."
      }
    ],
    "total": 591,
    "sid": "621096",
    "stock_news_url": "https://www.marketsmojo.com/news/colinz-laboratories-621096"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI SAST Regulations 2011",
      "datetime": "13-Dec-2025",
      "details": "Dear Sir Please find the attached discloser submitted by our Promoter Ms Vijaya Mani after the transmission of his Husband Shares to her name . Kindly take the note of the same. For COlinz Labs Ltd Director",
      "source": "BSE"
    },
    {
      "caption": "Submissions Of Disclosers Under Regulation 7(2) Of SEBI PIT Regulation 2015",
      "datetime": "13-Dec-2025",
      "details": "Dear Sir Please find the attached Disclosures of SEBI PIT Regulation 2015 submitted by our Promoter Ms Vijaya Mani after the transmission shares from her husband. Kindly take the note of the same. For Colinz Labs Ltd Director",
      "source": "BSE"
    },
    {
      "caption": "Regulation 10(6) Of SEBI (SAST) Regulation 29(2)",
      "datetime": "13-Dec-2025",
      "details": "Dear Sir Please find the attached Disclosure under Regulation 10(6) of SEBI SAST Regulation 29(2) given by our Promoter Ms. Vijaya Mani towards the transmission his shares from his Hus band Dr Mani L S after his dearth. Kindly take the note of the same. Director",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Colinz Labs falling/rising?

2025-12-16 00:31:17

Recent Price Performance and Market Context

Colinz Laboratories has demonstrated a remarkable rebound over the past week and month, with returns of +11.36% and +14.65% respectively, significantly outpacing the Sensex benchmark, which posted marginal gains of +0.13% and +0.77% over the same periods. This outperformance is particularly striking given the stock's year-to-date decline of nearly 30%, contrasting with the Sensex's positive 9.05% gain. The divergence suggests that investors are beginning to reassess the stock's prospects, possibly anticipating a turnaround or capitalising on recent technical signals.

Over the longer term, Colinz Labs has delivered a robust five-year return of +241.46%, well above the Sensex's +84.19%, underscoring its potential for substantia...

Read More

Colinz Labs Sees Revision in Market Evaluation Amidst Challenging Financial Trends

2025-12-09 10:10:07

Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry.

Read More

Why is Colinz Labs falling/rising?

2025-11-14 21:44:17

As of 14-Nov, Colinz Laboratories Ltd is experiencing a price increase, currently at 42.74, which reflects a rise of 0.94 or 2.25%. The stock has shown strong performance recently, gaining for four consecutive days and achieving a total return of 7.49% during this period. Additionally, it has outperformed its sector by 1.88%. In terms of returns compared to the benchmark, over the past week, the stock has increased by 2.91%, while the Sensex has risen by 1.62%. The stock's delivery volume has also seen a significant increase of 48.13% compared to the five-day average, indicating rising investor participation. However, it is important to note that there is no information available regarding any positive or negative factors that could further explain the stock's recent movement. Broader Market Context: In the short term, Colinz Laboratories Ltd has outperformed the Sensex, which suggests that investor sentim...

Read More

Colinz Laboratories Hits New 52-Week Low at Rs. 36.11

2025-11-13 09:58:38

Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance.

Read More

Colinz Laboratories Hits New 52-Week Low at Rs. 37.4

2025-11-11 14:13:49

Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market.

Read More

Why is Colinz Labs falling/rising?

2025-11-06 21:25:46

As of 06-Nov, Colinz Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 39.81, which represents a decrease of 4.42 or 9.99%. The stock has underperformed its sector by 9.22% today and has opened with a loss of 4.07%. It has touched an intraday low of Rs 39.81, indicating significant selling pressure. The stock has also fallen after two consecutive days of gains, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a notable drop in investor participation, with delivery volume falling by 77.12% against the 5-day average. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Colinz Laboratories Ltd's performance over the past week shows a decline of 9.48%, while the benchmark Sensex has only decrea...

Read More

Colinz Laboratories Ltd Faces 9.99% Decline Amid Significant Selling Pressure and Ongoing Losses

2025-11-06 14:35:28

Colinz Laboratories Ltd is experiencing substantial selling pressure, with its stock declining significantly over various time frames. The company has faced consecutive losses, underperforming against the Sensex and its sector. Factors contributing to this trend include trading below key moving averages and ongoing challenges in its market position.

Read More

Are Colinz Labs latest results good or bad?

2025-11-04 19:45:34

Colinz Laboratories' latest financial results for Q2 FY26 reveal a complex operational landscape characterized by significant challenges. The company reported net sales of ₹1.39 crores, reflecting a decline of 11.46% from the previous quarter and a more pronounced year-on-year decrease of 25.27%. This trend indicates ongoing difficulties in maintaining revenue momentum, as the company has now experienced negative growth in sales for several consecutive quarters. Despite the revenue decline, Colinz Laboratories reported a net profit of ₹0.14 crores, which represents a sequential improvement of 16.67% compared to the previous quarter. However, this figure is down 12.50% year-on-year, suggesting that while there may be some short-term resilience in net profit, the overall financial health remains under pressure due to the declining top-line performance. Operating margins also faced significant compression, w...

Read More

Is Colinz Labs overvalued or undervalued?

2025-11-04 08:06:53

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics. Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers....

Read More

View All News